![](https://adventls.com/wp-content/uploads/2022/12/Advent_Portfolio_aravive_L.jpg)
Therapies targeting survival pathways for cancer
Aravive, Inc., is a clinical stage biotechnology company focused on developing new therapies that target important survival pathways for both solid tumors as well as hematologic malignancies.
Our primary therapeutic focus is the GAS6-AXL pathway, where AXL receptor signaling plays a critical role in multiple types of malignancies by promoting metastasis and cancer cell survival.
CEO Gail McIntyre
Advent Contact Shahzad Malik